Salient Bio develops microbiome-based, non-invasive diagnostics using its proprietary SIGNAL platform, which applies automation, microbiome data analysis, and machine learning to generate disease signatures. The company is commercializing an at-home IBD diagnostic test intended to accelerate diagnosis and distinguish IBD from conditions with similar symptoms, potentially reducing unnecessary colonoscopies. It plans to leverage SIGNAL to accelerate research into conditions that disproportionately affect women and expand its women’s health offerings. Salient Bio operates an ISO 17025 accredited testing and prototyping laboratory in London focused on microbiome analysis, process standardization, automation, and machine learning-based data analysis. The company has raised a £2.35 million seed round to support the commercial launch of its IBD test. Founders Marta Ciechonska and Miles Priestman emphasize accessible, non-invasive testing solutions to shorten diagnostic timelines and enable earlier treatment.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2025